T. Mrkvan

发表

HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro.

K. Ulbrich, V. Šubr, M. Kovar, 2004, Journal of controlled release : official journal of the Controlled Release Society.

Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice

K. Ulbrich, V. Šubr, T. Mrkvan, 2006, Cancer Immunology, Immunotherapy.

Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging

J. Stoddard, T. Mrkvan, P. Lambert, 2017, npj Aging and Mechanisms of Disease.

1956. Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial

L. Cámpora, T. Mrkvan, C. Hervé, 2018, Open Forum Infectious Diseases.

HPMA-Anticancer Drug Conjugates

K. Ulbrich, V. Šubr, M. Kovar, 2010 .

N-(2-Hydroxypropyl)methacrylamide-Based Polymer Conjugates with pH-Controlled Activation of Doxorubicin. I. New Synthesis, Physicochemical Characterization and Preliminary Biological Evaluation

K. Ulbrich, T. Etrych, T. Mrkvan, 2008 .

Preclinical Evaluation of Linear HPMA-Doxorubicin Conjugates with pH-Sensitive Drug Release: Efficacy, Safety, and Immunomodulating Activity in Murine Model

K. Ulbrich, L. Kovář, T. Etrych, 2009, Pharmaceutical Research.

Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data.

K. Ulbrich, V. Šubr, T. Etrych, 2003, Journal of controlled release : official journal of the Controlled Release Society.

Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck

M. Chovanec, T. Mrkvan, B. Říhová, 2009, Journal of cellular and molecular medicine.

Overcoming immunoescape mechanisms of BCL1 leukemia and induction of CD8+ T-cell-mediated BCL1-specific resistance in mice cured by targeted polymer-bound doxorubicin.

K. Ulbrich, L. Kovář, T. Etrych, 2008, Cancer research.

Doxorubicin Resistance in Mice Cured by Targeted Polymer-Bound Mediated BCL 1-Specific − T-Cell + and Induction of CD 8 Overcoming Immunoescape Mechanisms of BCL 1 Leukemia

K. Ulbrich, L. Kovář, T. Etrych, 2008 .

Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage

T. Mrkvan, L. Bakaletz, D. Borys, 2017, Expert review of vaccines.

Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience

T. Mrkvan, S. Pelton, D. Borys, 2018, Expert review of vaccines.

Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention

E. Ledent, T. Mrkvan, A. Didierlaurent, 2018, Expert review of vaccines.

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials

H. Ikematsu, Shinn-Jang Hwang, T. Mrkvan, 2019, Human vaccines & immunotherapeutics.

Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children

T. Mrkvan, O. Leeuwenkamp, S. Iwata, 2014, Infectious Diseases and Therapy.

New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting.

K. Ulbrich, T. Etrych, T. Mrkvan, 2008, Journal of controlled release : official journal of the Controlled Release Society.

Novel Approach of Cancer Immunotherapy IL-2 and Anti-IL-2 Monoclonal Antibody As ofT Cells and NK Cells Driven by Complexes + In Vivo Expansion of Activated Naive CD 8

T. Mrkvan, B. Říhová, M. Kovář, 2009 .

Induction of Systemic Antitumour Resistance with Targeted Polymers

K. Ulbrich, V. Šubr, T. Mrkvan, 2005, Scandinavian journal of immunology.

HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.

K. Ulbrich, T. Etrych, T. Mrkvan, 2003, Journal of controlled release : official journal of the Controlled Release Society.

Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.

K. Ulbrich, T. Etrych, T. Mrkvan, 2008, Journal of controlled release : official journal of the Controlled Release Society.

In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression

J. Sprent, O. Boyman, S. Grey, 2009, The Journal of experimental medicine.

In Vivo Expansion of Activated Naive CD8+ T Cells and NK Cells Driven by Complexes of IL-2 and Anti-IL-2 Monoclonal Antibody As Novel Approach of Cancer Immunotherapy1

T. Mrkvan, B. Říhová, M. Kovář, 2009, The Journal of Immunology.

The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.

T. Mrkvan, D. Curran, Xuan Wang, 2019, Vaccine.

Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging

J. Stoddard, T. Mrkvan, P. Lambert, 2017, npj Aging and Mechanisms of Disease.

Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.

K. Ulbrich, T. Etrych, T. Mrkvan, 2007, Journal of controlled release : official journal of the Controlled Release Society.

Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.

K. Ulbrich, T. Etrych, T. Mrkvan, 2006, Journal of controlled release : official journal of the Controlled Release Society.

Reply to Farkouh RA et al. Comment on “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”

T. Mrkvan, O. Leeuwenkamp, S. Iwata, 2015, Infectious Diseases and Therapy.

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany

T. Mrkvan, D. Curran, L. Varghese, 2017, Human vaccines & immunotherapeutics.

The Comparative Efficacy, Safety, And Reactogenicity, of Herpes Zoster Vaccines: A Network Meta-Analysis

T. Mrkvan, D. Curran, J. McElhaney, 2018 .

Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity.

K. Ulbrich, T. Etrych, T. Mrkvan, 2005, Journal of controlled release : official journal of the Controlled Release Society.

2905. Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling

T. Mrkvan, T. Schwarz, L. Rombo, 2019, Open Forum Infectious Diseases.

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination

T. Mrkvan, T. Schwarz, L. Rombo, 2020, The Journal of infectious diseases.

Cytotoxic and Immunomodulatory Activites of Polymer-Bound Drugs

K. Ulbrich, V. Šubr, T. Etrych, 2004 .

The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line.

K. Ulbrich, L. Kovář, T. Mrkvan, 2007, Bioconjugate chemistry.

New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting.

T. Etrych, T. Mrkvan, B. Říhová, 2008, Journal of controlled release : official journal of the Controlled Release Society.